|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang
H, Zhang X, Jiang JT and Wu CP: PD-1/PD-L1 pathway in
non-small-cell lung cancer and its relation with EGFR mutation. J
Transl Med. 13:52015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim MY, Koh J, Kim S, Go H, Jeon YK and
Chung DH: Clinicopathological analysis of PD-L1 and PD-L2
expression in pulmonary squamous cell carcinoma: Comparison with
tumor-infiltrating T cells and the status of oncogenic drivers.
Lung Cancer. 88:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JK, Hahn S, Kim DW, Suh KJ, Keam B,
Kim TM, Lee SH and Heo DS: Epidermal growth factor receptor
tyrosine kinase inhibitors vs conventional chemotherapy in
non-small cell lung cancer harboring wild-type epidermal growth
factor receptor: A meta-analysis. JAMA. 311:1430–1437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cross DA, Ashton SE, Ghiorghiu S, Eberlein
C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ,
et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated
resistance to EGFR inhibitors in lung cancer. Cancer Discov.
4:1046–1061. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Azuma K, Ota K, Kawahara A, Hattori S,
Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et
al: Association of PD-L1 overexpression with activating EGFR
mutations in surgically resected nonsmall-cell lung cancer. Ann
Oncol. 25:1935–1940. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang Y, Fang W, Zhang Y, Hong S, Kang S,
Yan Y, Chen N, Zhan J, He X, Qin T, et al: The association between
PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced
non-small cell lung cancer patients treated with EGFR-TKIs.
Oncotarget. 6:14209–14219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
D’Incecco A, Andreozzi M, Ludovini V,
Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J,
Coppi E, et al: PD-1 and PD-L1 expression in molecularly selected
non-small-cell lung cancer patients. Br J Cancer. 112:95–102. 2015.
View Article : Google Scholar :
|
|
12
|
Afreen S and Dermime S: The
immunoinhibitory B7-H1 molecule as a potential target in cancer:
Killing many birds with one stone. Hematol Oncol Stem Cell Ther.
7:1–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muenst S, Soysal SD, Tzankov A and Hoeller
S: The PD-1/PD-L1 pathway: Biological background and clinical
relevance of an emerging treatment target in immunotherapy. Expert
Opin Ther Targets. 19:201–211. 2015. View Article : Google Scholar
|
|
14
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wölfle SJ, Strebovsky J, Bartz H, Sähr A,
Arnold C, Kaiser C, Dalpke AH and Heeg K: PD-L1 expression on
tolerogenic APCs is controlled by STAT-3. Eur J Immunol.
41:413–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cortez MA, Ivan C, Valdecanas D, Wang X,
Peltier HJ, Ye Y, Araujo L, Carbone DP, Shilo K, Giri DK, et al:
PDL1 regulation by p53 via miR-34. J Natl Cancer Inst. 108:1082015.
View Article : Google Scholar
|
|
19
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: A model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Keedy VL, Temin S, Somerfield MR, Beasley
MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA and
Giaccone G: American Society of Clinical Oncology provisional
clinical opinion: Epidermal growth factor receptor (EGFR) Mutation
testing for patients with advanced non-small-cell lung cancer
considering first-line EGFR tyrosine kinase inhibitor therapy. J
Clin Oncol. 29:2121–2127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI,
Park YM, Oh S, Shin JG, Yao S, Chen L, et al: Interferon regulatory
factor-1 is prerequisite to the constitutive expression and
IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett.
580:755–762. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Velcheti V, Schalper KA, Carvajal DE,
Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L
and Rimm DL: Programmed death ligand-1 expression in non-small cell
lung cancer. Lab Invest. 94:107–116. 2014. View Article : Google Scholar
|
|
23
|
Barber DL, Wherry EJ, Masopust D, Zhu B,
Allison JP, Sharpe AH, Freeman GJ and Ahmed R: Restoring function
in exhausted CD8 T cells during chronic viral infection. Nature.
439:682–687. 2006. View Article : Google Scholar
|
|
24
|
Abiko K, Matsumura N, Hamanishi J,
Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I
and Mandai M: IFN-γ from lymphocytes induces PD-L1 expression and
promotes progression of ovarian cancer. Br J Cancer. 112:1501–1509.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ritprajak P and Azuma M: Intrinsic and
extrinsic control of expression of the immunoregulatory molecule
PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol.
51:221–228. 2015. View Article : Google Scholar
|
|
26
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL,
et al: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra372012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu J, Hamrouni A, Wolowiec D, Coiteux V,
Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells
from multiple myeloma patients express B7-H1 (PD-L1) and increase
expression after stimulation with IFN-{gamma} and TLR ligands via a
MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 110:296–304.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Atefi M, Avramis E, Lassen A, Wong DJ,
Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et
al: Effects of MAPK and PI3K pathways on PD-L1 expression in
melanoma. Clin Cancer Res. 20:3446–3457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar
|
|
30
|
Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y,
Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, et al:
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with
elevated PD-L1 expression. Cancer Cell. 25:590–604. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin K, Cheng J, Yang T, Li Y and Zhu B:
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through
inhibiting NF-κB. Biochem Biophys Res Commun. 463:95–101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Huang S, Gong D, Qin Y and Shen
Q: Programmed death-1 upregulation is correlated with dysfunction
of tumor-infiltrating CD8+ T lymphocytes in human
non-small cell lung cancer. Cell Mol Immunol. 7:389–395. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen YB, Mu CY and Huang JA: Clinical
significance of programmed death-1 ligand-1 expression in patients
with non-small cell lung cancer: A 5-year-follow-up study. Tumori.
98:751–755. 2012.
|
|
34
|
Mu CY, Huang JA, Chen Y, Chen C and Zhang
XG: High expression of PD-L1 in lung cancer may contribute to poor
prognosis and tumor cells immune escape through suppressing tumor
infiltrating dendritic cells maturation. Med Oncol. 28:682–688.
2011. View Article : Google Scholar
|
|
35
|
Robert L, Ribas A and Hu-Lieskovan S:
Combining targeted therapy with immunotherapy. Can 1+1 equal more
than 2? Semin Immunol. 28:73–80. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wargo JA, Cooper ZA and Flaherty KT:
Universes collide: Combining immunotherapy with targeted therapy
for cancer. Cancer Discov. 4:1377–1386. 2014. View Article : Google Scholar : PubMed/NCBI
|
